ArticleAdvances in therapy2023

Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.

Maria Fasshauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.